Salts of aza-fused ring amide compounds, their crystal forms and uses thereof
By preparing salts of aza-fused-cyclic amide compounds, especially their crystalline forms of hydrochloride, sulfate, and methanesulfonate, the problem of TRK inhibitor resistance has been solved, achieving effective inhibition of TRK kinase and tumor growth, showing promising pharmaceutical potential.
Patent Information
- Application Number
- CN202211426259.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-11-15
- Filing Date
- 2022-11-14
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-11-14
AI Technical Summary
Existing TRK inhibitors face the problem of drug resistance. Mutations in the NTRK kinase domain lead to conformational changes or alterations in ATP binding affinity, affecting binding to the target. Second-generation TRK inhibitors such as LOXO-195 and TPX-005 still require further development of new drugs.
Salts of aza-fused cyclic amide compounds of formula (A-1), including crystalline forms such as hydrochloride, sulfate, and methanesulfonate, are provided by reaction with an acid, exhibiting specific X-ray powder diffraction patterns and differential scanning calorimetry profiles, for use in the preparation of pharmaceutical compositions to treat TRK-mediated diseases.
It achieved excellent inhibitory activity against a variety of kinases and mutants, with an in vitro cell inhibitory activity IC50 below 10 nM, significant in vivo antitumor effects, and good potential for drug development. It can inhibit the phosphorylation of TRK, PLCγ1, and AKT in tumor tissues.
Smart Images

Figure CN116120322B_ABST
Abstract
Description
[0001] The present invention claims the priority benefit of the prior application of patent application number 202111345223.8 filed by the applicant with the State Intellectual Property Office of China on November 15, 2021, entitled “Salts of Aza-fused Cyclic Amide Compounds and Uses Thereof”. The full text of the prior application is incorporated into this application by reference. Technical Field
[0002] The present invention belongs to the field of pharmaceutical chemistry, and in particular relates to salts of aza-fused-ring amide compounds, their crystal forms and uses. Background Art
[0003] Tropomyosin-related kinase or tropomyosin receptor kinase (TRK) is a type of nerve growth factor receptor. Its family consists of three highly homologous subtypes, TRKA, TRKB and TRKC, which are encoded by neurotrophic receptor tyrosine kinase 1 (NTRK1), NTRK2 and NTRK3 genes, respectively. When the TRK receptor protein binds to the corresponding ligand, it can achieve different physiological functions by activating downstream signaling pathways, such as the RAS / MAPK pathway, the PLCγ pathway and the PI3K pathway. TRK family proteins are normally expressed in neural tissues, involved in the differentiation and survival of nerve cells, and the formation of axons and dendrites, and play an important role in embryonic development and the maintenance of normal function of the nervous system.
[0004] TRK kinase is activated in malignant tumors through a variety of mechanisms, mainly structural rearrangement and expression changes. For example, the gene encoding TRK kinase NTRK rearranges with other genes to produce a fusion oncogene, which causes TRK kinase to change in structure and expression. It is no longer regulated and controlled by nerve growth factor ligands, and is constitutively activated, promoting tumor development. In addition, gene sequencing results also show that TRK kinase is closely related to the occurrence, metastasis and deterioration of various tumors, and is expressed in a variety of tumors, such as non-small cell lung cancer, colorectal cancer, melanoma, gallbladder cancer, thyroid cancer, malignant glioma, etc.
[0005] Currently, the first-generation TRK inhibitors Larotrectinib (LOXO-101) and Entrectinib (RXDX-101) were approved for marketing by the U.S. Food and Drug Administration (FDA) in 2018 and 2019, respectively. Larotrectinib is a potent, oral, selective tropomyosin receptor kinase inhibitor. Its efficacy data were announced as early as the ASCO conference in June 2017. In Phase I and Phase II clinical trials, a total of 55 subjects were recruited, of which 46 evaluable patients had an overall response rate (ORR) of 78%. Entrectinib is a potent inhibitor of TRK, ROS1, and ALK proteins, and can pass through the blood-brain barrier. In Phase I clinical trials, the ORR of 24 evaluable patients was 79%.
[0006]
[0007] Similar to other targeted drugs, TRK inhibitors also face the problem of drug resistance. Mutations in the NTRK kinase region can cause conformational changes in the TRK family protein kinase domain or changes in binding affinity with ATP, thereby affecting the binding of TRK inhibitors to targets. Mutation types include G595R, G639R, G667C, etc. In order to solve the drug resistance problem of the first-generation TRK inhibitors, although the second-generation TRK inhibitors such as LOXO-195 and TPX-005 are already under research, new drugs still need to be developed.
[0008] Summary of the invention
[0009] In order to improve the above problems, the present invention provides a salt of a compound represented by formula (A-1):
[0010]
[0011] Wherein, HA is an acid, such as hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid or benzenesulfonic acid; more preferably hydrochloric acid, sulfuric acid or methanesulfonic acid; further preferably hydrochloric acid or sulfuric acid;
[0012] n is an integer or half integer of 1 / 2 to 4; preferably an integer or half integer of 1 / 2 to 3; more preferably 0.5, 1, 1.5 or 2.
[0013] According to an embodiment of the present invention, the salt of the compound represented by formula (A-1) is a salt of the compound represented by formula (A-1) in a crystalline form.
[0014] According to an embodiment of the present invention, the salt of the compound represented by formula (A-1) is a hydrochloride represented by formula (1):
[0015]
[0016] Wherein, n is 0.5, 1, 1.5 or 2; preferably 1 or 2.
[0017] According to an embodiment of the present invention, the hydrochloride represented by formula (1) is the hydrochloride represented by formula (1-1):
[0018]
[0019] According to an embodiment of the present invention, the hydrochloride represented by formula (1-1) is a crystalline form of the hydrochloride represented by formula (1-1).
[0020] According to an embodiment of the present invention, the hydrochloride salt represented by formula (1-1) in the crystalline form is its crystalline form I, and using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 6.3°, 11.6°, 17.1°, 19.1°.
[0021] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the hydrochloride represented by formula (1-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 6.3°, 11.6°, 11.8°, 17.1°, 19.1°, 19.3°.
[0022] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the hydrochloride represented by formula (1-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 6.3°, 7.5°, 11.6°, 11.8°, 12.7°, 17.1°, 19.1°, 19.3°.
[0023] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the hydrochloride salt represented by (Formula 1-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 6.3°, 7.5°, 11.6°, 11.8°, 12.7°, 15.1°, 17.1°, 19.1°, 19.3°, 25.8°.
[0024] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the hydrochloride represented by the formula (1-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 6.3°, 7.5°, 11.6°, 11.8°, 12.7°, 15.1°, 16.3°, 17.1°, 19.1°, 19.3°, 24.7°, 25.8°.
[0025] According to an embodiment of the present invention, the crystalline form I of the hydrochloride salt represented by the formula (1-1) is irradiated with Cu-Kα, which has substantially Figure 1 The X-ray powder diffraction pattern is shown.
[0026] According to an embodiment of the present invention, the differential scanning calorimetry curve of the crystalline form I of the hydrochloride represented by formula (1-1) has an endothermic peak at 174.7±5°C.
[0027] According to an embodiment of the present invention, the differential scanning calorimetry curve of the crystalline form I of the hydrochloride salt represented by formula (1-1) has endothermic peaks at 62.61±5°C, 119.14±5°C and 174.70±5°C.
[0028] According to an embodiment of the present invention, the crystalline form I of the hydrochloride salt represented by formula (1-1) has substantially Figure 2 DSC spectrum shown.
[0029] According to an embodiment of the present invention, the thermogravimetric analysis curve of the hydrochloride crystal form I represented by formula (1-1) has a weight loss of 3.2847%±0.2% between (120-170)±5°C.
[0030] According to some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I of the hydrochloride represented by the formula (1-1) has a weight loss of 3.2847%±0.2% between 115-175°C or 120-175°C or 125-175°C or 115-170°C or 120-170°C or 125-170°C or 115-165°C or 120-165°C or 125-165°C.
[0031] According to some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I of the hydrochloride represented by formula (1-1) has a weight loss of 3.2847%±0.2% between 120 and 170°C.
[0032] According to an embodiment of the present invention, the thermogravimetric analysis curve of the crystalline form I of the hydrochloride salt represented by the formula (1-1) has a weight loss of 1.5910%±0.2% between (room temperature~50℃)±5℃, a weight loss of 1.9155%±0.2% between (50~120)±5℃, and a weight loss of 3.2847%±0.2% between (120~170)±5℃.
[0033] According to some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I of the hydrochloride salt represented by formula (1-1) has a weight loss of 1.5910% ± 0.2% between room temperature and 45°C or room temperature and 50°C or room temperature and 55°C, and a weight loss of 1.5910% ± 0.2% between 45 and 115°C or 45 and 120°C or 45 and 125°C or 50 and 115°C or 50 and 120°C or 50 and 125°C or 55 and 115°C or There is a weight loss of 1.9155%±0.2% at 55-120°C or 55-125°C, and a weight loss of 3.2847%±0.2% at 115-175°C or 120-175°C or 125-175°C or 115-170°C or 120-170°C or 125-170°C or 115-165°C or 120-165°C or 125-165°C.
[0034] According to some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I of the hydrochloride salt represented by formula (1-1) has a weight loss of 1.5910%±0.2% between room temperature and 50°C, a weight loss of 1.9155%±0.2% between 50°C and 120°C, and a weight loss of 3.2847%±0.2% between 120°C and 170°C.
[0035] According to an embodiment of the present invention, the crystalline form I of the hydrochloride salt represented by formula (1-1) has substantially Figure 2 TGA spectrum shown.
[0036] According to an embodiment of the present invention, the salt of the compound represented by formula (A-1) is a sulfate represented by formula (2):
[0037]
[0038] Wherein, n is 0.5 or 1, preferably 0.5.
[0039] According to an embodiment of the present invention, the sulfate represented by formula (2) is a sulfate represented by formula (2-1):
[0040]
[0041] According to an embodiment of the present invention, the sulfate represented by formula (2-1) is a sulfate represented by formula (2-1) in a crystalline form.
[0042] According to an embodiment of the present invention, the sulfate represented by formula (2-1) in the crystalline form is its crystalline form I, and using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2°): 7.8°, 17.5°, 18.9°, 19.7°.
[0043] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the sulfate represented by formula (2-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 7.8°, 17.5°, 18.9°, 19.7°, 24.6°.
[0044] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the sulfate represented by formula (2-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 7.8°, 12.5°, 17.5°, 18.9°, 19.7°, 23.6°, 24.6°.
[0045] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the sulfate represented by formula (2-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 7.8°, 12.5°, 17.5°, 18.9°, 19.4°, 19.7°, 23.6°, 24.6°, 25.3°.
[0046] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the sulfate represented by formula (2-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 7.8°, 12.5°, 17.5°, 18.9°, 19.4°, 19.7°, 20.5°, 23.6°, 24.6°, 25.3°, 26.1°.
[0047] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the sulfate represented by formula (2-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 5.7°, 7.8°, 12.5°, 17.5°, 18.9°, 19.4°, 19.7°, 20.5°, 23.6°, 24.6°, 25.3°, 26.1°, 31.7°, 33.9°.
[0048] According to an embodiment of the present invention, the crystalline form I of the sulfate salt represented by formula (2-1) has substantially the following properties when irradiated with Cu-Kα. Figure 3 The X-ray powder diffraction pattern is shown.
[0049] According to an embodiment of the present invention, the differential scanning calorimetry curve of the sulfate crystal form I represented by formula (2-1) has an endothermic peak at 241±5°C.
[0050] According to an embodiment of the present invention, the differential scanning calorimetry curve of the sulfate crystal form I represented by formula (2-1) has endothermic peaks at 235°C±5°C and 241±5°C.
[0051] According to an embodiment of the present invention, the crystalline form I of the sulfate represented by formula (2-1) has substantially Figure 4 DSC spectrum shown.
[0052] According to an embodiment of the present invention, the crystalline form I of the sulfate salt represented by formula (2-1) has substantially Figure 4 TGA spectrum shown.
[0053] According to an embodiment of the present invention, the sulfate represented by formula (2-1) in the crystalline form is form II, and using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks (±0.2°) at the following 2θ angles: 5.5, 7.6, 16.5, 18.9.
[0054] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the sulfate crystal form II represented by formula (2-1) has characteristic diffraction peaks (±0.2°) at the following 2θ angles: 3.9, 5.5, 7.6, 16.5, 18.9.
[0055] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the sulfate crystal form II represented by formula (2-1) has characteristic diffraction peaks (±0.2°) at the following 2θ angles: 3.9, 5.5, 7.6, 10.9, 16.5, 18.9.
[0056] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the sulfate crystal form II represented by formula (2-1) has characteristic diffraction peaks (±0.2°) at the following 2θ angles: 3.9, 5.5, 7.6, 10.9, 16.0, 16.5, 18.9.
[0057] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the sulfate crystal form II represented by formula (2-1) has characteristic diffraction peaks (±0.2°) at the following 2θ angles: 3.9, 5.5, 7.6, 10.9, 12.6, 16.0, 16.5, 18.9.
[0058] According to an embodiment of the present invention, the crystalline form II of the sulfate salt represented by formula (2-1) has substantially the following properties when irradiated with Cu-Kα: Figure 5 The X-ray powder diffraction pattern is shown.
[0059] According to an embodiment of the present invention, the differential scanning calorimetry curve of the crystal form II of the sulfate represented by formula (2-1) has an endothermic peak at 227.22±5°C.
[0060] According to an embodiment of the present invention, the crystalline form II of the sulfate salt represented by formula (2-1) has substantially Figure 6 DSC spectrum shown.
[0061] According to an embodiment of the present invention, the crystalline form II of the sulfate salt represented by formula (2-1) has substantially Figure 6 TGA spectrum shown.
[0062] According to an embodiment of the present invention, the salt of the compound represented by formula (A-1) is a methanesulfonate represented by formula (3):
[0063]
[0064] Wherein, n is 0.5, 1, 1.5 or 2; preferably 1.
[0065] According to an embodiment of the present invention, the methanesulfonate represented by formula (3) is a methanesulfonate represented by formula (3-1):
[0066]
[0067] According to an embodiment of the present invention, the methanesulfonate represented by formula (3-1) is a crystalline form of the methanesulfonate represented by formula (3-1).
[0068] According to an embodiment of the present invention, the mesylate salt represented by formula (3-1) in the crystalline form is its crystalline form I, and using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2°): 6.8°, 8.1°, 10.6°, 11.9°.
[0069] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the mesylate represented by formula (3-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 6.8°, 8.1°, 10.6°, 11.9°, 15.5°.
[0070] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the mesylate represented by formula (3-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 6.8°, 8.1°, 10.6°, 11.9°, 15.5°, 18.9°, 21.1°.
[0071] According to an embodiment of the present invention, the X-ray powder diffraction pattern of the crystalline form I of the mesylate represented by formula (3-1) has characteristic diffraction peaks at the following 2θ angles (±0.2°): 6.8°, 8.1°, 10.6°, 11.9°, 15.5°, 18.0°, 18.9°, 21.1°, 26.3°.
[0072] According to an embodiment of the present invention, the crystalline form I of the mesylate salt represented by formula (3-1) is irradiated with Cu-Kα, which has substantially Figure 7 The X-ray powder diffraction pattern is shown.
[0073] According to an embodiment of the present invention, the differential scanning calorimetry curve of the crystalline form I of the mesylate represented by formula (3-1) has an endothermic peak at 180.62±5°C.
[0074] According to an embodiment of the present invention, the differential scanning calorimetry curve of the crystalline form I of the mesylate represented by formula (3-1) has endothermic peaks at 71.95±5°C and 180.62±5°C.
[0075] According to an embodiment of the present invention, the crystalline form I of the mesylate salt represented by formula (3-1) has substantially Figure 8 DSC spectrum shown.
[0076] According to an embodiment of the present invention, the thermogravimetric analysis curve of the crystal form I of the mesylate represented by formula (3-1) has a weight loss of 1.1072%±0.2% between (100-200°C)±5°C.
[0077] According to some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I of the mesylate represented by formula (3-1) has a weight loss of 1.1072%±0.2% between 95-205°C or 100-205°C or 105-205°C or 95-200°C or 100-200°C or 105-200°C or 95-195°C or 100-195°C or 105-195°C.
[0078] According to some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I of the mesylate represented by formula (3-1) has a weight loss of 1.1072%±0.2% between 100 and 200°C.
[0079] According to an embodiment of the present invention, the thermogravimetric analysis curve of the crystalline form I of the mesylate represented by formula (3-1) has a weight loss of 1.9565%±0.2% between (room temperature ~ 100°C)±5°C, and a weight loss of 1.1072%±0.2% between (100~200°C)±5°C.
[0080] According to some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I of the mesylate represented by formula (3-1) has a weight loss of 1.9565%±0.2% between room temperature and 95°C or room temperature and 100°C or room temperature and 105°C, and a weight loss of 1.1072%±0.2% between 95 and 205°C or 100 and 205°C or 105 and 205°C or 95 and 200°C or 100 and 200°C or 105 and 200°C or 105 and 195°C or 100 and 195°C or 95 and 195°C.
[0081] According to some embodiments of the present invention, the thermogravimetric analysis curve of the crystalline form I of the mesylate represented by formula (3-1) has a weight loss of 1.9565%±0.2% between room temperature and 100°C, and a weight loss of 1.1072%±0.2% between 100 and 200°C.
[0082] According to an embodiment of the present invention, the crystalline form I of the mesylate salt represented by formula (3-1) has substantially Figure 8 TGA spectrum shown.
[0083] According to an embodiment of the present invention, the present invention also provides a pharmaceutical composition, comprising a salt of the compound represented by the aforementioned formula (A-1) or a salt of the compound represented by the aforementioned crystalline form of formula (A-1), optionally further comprising one or more pharmaceutically acceptable carriers.
[0084] According to an embodiment of the present invention, the above-mentioned pharmaceutical composition comprises the hydrochloride of the compound represented by the aforementioned formula (1), the hydrochloride of the compound represented by the aforementioned formula (1-1) or the crystalline form of the hydrochloride of the compound represented by the aforementioned formula (1-1), and optionally, further comprises one or more pharmaceutically acceptable carriers.
[0085] According to an embodiment of the present invention, the above-mentioned pharmaceutical composition comprises a sulfate of the compound represented by the aforementioned formula (2), a sulfate of the compound represented by the aforementioned formula (2-1), a crystalline form of the sulfate of the compound represented by the aforementioned formula (2-1), a crystalline form I of the sulfate of the compound represented by the aforementioned formula (2-1), or a crystalline form II of the sulfate of the compound represented by the aforementioned formula (2-1), and optionally, further comprises one or more pharmaceutically acceptable carriers.
[0086] According to an embodiment of the present invention, the above-mentioned pharmaceutical composition comprises the mesylate of the compound represented by the aforementioned formula (3), the mesylate of the compound represented by the aforementioned formula (3-1), or the crystalline form of the mesylate of the compound represented by the aforementioned formula (3-1), and optionally, further comprises one or more pharmaceutically acceptable carriers.
[0087] According to an embodiment of the present invention, the present invention also provides a salt of the compound represented by the aforementioned formula (A-1), a salt of the compound represented by the aforementioned formula (A-1) in crystalline form, a hydrochloride of the compound represented by the aforementioned formula (1), a hydrochloride of the compound represented by the aforementioned formula (1-1), a hydrochloride of the compound represented by the aforementioned formula (1-1) in crystalline form, a crystalline form I of the hydrochloride of the compound represented by the aforementioned formula (1-1), a sulfate of the compound represented by the aforementioned formula (2-1), a sulfate of the compound represented by the aforementioned formula (2-1) in crystalline form, a crystalline form I of the sulfate of the compound represented by the aforementioned formula (2-1), a crystalline form II of the sulfate of the compound represented by the aforementioned formula (2-1), a methanesulfonate of the compound represented by the aforementioned formula (3), a methanesulfonate of the compound represented by the aforementioned formula (3-1), a methanesulfonate of the compound represented by the aforementioned formula (3-1) in crystalline form, a crystalline form I of the methanesulfonate of the compound represented by the aforementioned formula (3-1), or the aforementioned pharmaceutical composition as a drug or for use in the preparation of a drug.
[0088] According to an embodiment of the present invention, the medicament is used to treat pain diseases, cell proliferative diseases, inflammatory diseases, neurodegenerative diseases or infectious diseases.
[0089] According to an embodiment of the present invention, the medicament is used for preventing and / or treating diseases mediated by one or more of TRK, ROS1 or ALK.
[0090] According to an embodiment of the present invention, the drug is used to prevent and / or treat tumors positive for NTRK gene rearrangement / fusion and / or drug-resistant mutations, or tumors positive for ROS1 gene rearrangement / fusion and / or drug-resistant mutations; preferably, the tumor is a solid tumor or a hematological tumor; further preferably, the tumor is a solid tumor.
[0091] According to an embodiment of the present invention, the NTRK resistance mutation is NTRK1-G595R, NTRK1-G667C, NTRK3-G623R or NTRK3-G696A; preferably, the NTRK resistance mutation is NTRK1-G595R, NTRK1-G667C or NTRK3-G623R; further preferably, the NTRK resistance mutation is NTRK1-G595R or NTRK1-G667C.
[0092] According to an embodiment of the present invention, the present invention also provides a salt of the compound represented by the aforementioned formula (A-1), a salt of the compound represented by the aforementioned formula (A-1) in crystalline form, a hydrochloride of the compound represented by the aforementioned formula (1), a hydrochloride of the compound represented by the aforementioned formula (1-1), a hydrochloride of the compound represented by the aforementioned formula (1-1) in crystalline form, a crystalline form I of the hydrochloride of the compound represented by the aforementioned formula (1-1), a sulfate of the compound represented by the aforementioned formula (2-1), a sulfate of the compound represented by the aforementioned formula (2-1), a crystalline form of the compound represented by the aforementioned formula (2-1) The sulfate of the compound, the crystalline form I of the sulfate of the compound represented by the aforementioned formula (2-1), the crystalline form II of the sulfate of the compound represented by the aforementioned formula (2-1), the methanesulfonate of the compound represented by the aforementioned formula (3), the methanesulfonate of the compound represented by the aforementioned formula (3-1), the methanesulfonate of the compound represented by the aforementioned crystalline form of formula (3-1), the crystalline form I of the methanesulfonate of the compound represented by the aforementioned formula (3-1), or at least one of the aforementioned pharmaceutical compositions, are used to prevent and / or treat diseases mediated by one or more of TRK, ROS1 or ALK.
[0093] According to an embodiment of the present invention, the present invention also provides a method for preventing and / or treating a disease, wherein the disease is selected from a pain disease, a cell proliferative disease, an inflammatory disease, a neurodegenerative disease or an infectious disease, the method comprising: administering to a patient a therapeutically effective amount of a salt of the compound represented by the aforementioned formula (A-1), a crystalline salt of the compound represented by the aforementioned formula (A)-1, a hydrochloride of the compound represented by the aforementioned formula (1), a hydrochloride of the compound represented by the aforementioned formula (1-1), a crystalline hydrochloride of the compound represented by the aforementioned formula (1-1), a hydrochloride of the compound represented by the aforementioned formula (1-1), a hydrochloride of the compound represented by the aforementioned formula (1-1), a hydrochloride of the compound represented by the aforementioned formula (1-1), and a hydrochloride of the compound represented by the aforementioned formula (1-1). Crystal form I, a sulfate of the compound represented by the aforementioned formula (2), a sulfate of the compound represented by the aforementioned formula (2-1), a sulfate of the compound represented by the aforementioned formula (2-1) in the aforementioned crystalline form, a crystal form I of the sulfate of the compound represented by the aforementioned formula (2-1), a crystal form II of the sulfate of the compound represented by the aforementioned formula (2-1), a methanesulfonate of the compound represented by the aforementioned formula (3), a methanesulfonate of the compound represented by the aforementioned formula (3-1), a methanesulfonate of the compound represented by the aforementioned formula (3-1) in the aforementioned crystalline form, a crystal form I of the methanesulfonate of the compound represented by the aforementioned formula (3-1), or the aforementioned pharmaceutical composition.
[0094] According to an embodiment of the present invention, the present invention also provides a method for preventing and / or treating a disease mediated by one or more of TRK, ROS1 or ALK, comprising: administering to a patient a therapeutically effective amount of a salt of the compound represented by the aforementioned formula (A-1), a crystalline salt of the compound represented by the aforementioned formula (A)-1, a hydrochloride of the compound represented by the aforementioned formula (1), a hydrochloride of the compound represented by the aforementioned formula (1-1), a crystalline hydrochloride of the compound represented by the aforementioned formula (1-1), a crystalline hydrochloride of the compound represented by the aforementioned formula (1-1), a crystalline form I of the hydrochloride of the compound represented by the aforementioned formula (2 ), the sulfate of the compound represented by the aforementioned formula (2-1), the sulfate of the compound represented by the aforementioned crystalline form of the compound represented by the aforementioned formula (2-1), the crystalline form I of the sulfate of the compound represented by the aforementioned formula (2-1), the crystalline form II of the sulfate of the compound represented by the aforementioned formula (2-1), the methanesulfonate of the compound represented by the aforementioned formula (3), the methanesulfonate of the compound represented by the aforementioned formula (3-1), the methanesulfonate of the compound represented by the aforementioned crystalline form of the compound represented by the aforementioned formula (3-1), the crystalline form I of the methanesulfonate of the compound represented by the aforementioned formula (3-1), or the aforementioned pharmaceutical composition.
[0095] According to an embodiment of the present invention, the above-mentioned disease is selected from pain diseases, cell proliferative diseases, inflammatory diseases, neurodegenerative diseases or infectious diseases.
[0096] According to an embodiment of the present invention, the above-mentioned disease is a tumor positive for NTRK gene rearrangement / fusion and / or drug-resistant mutation, or a tumor positive for ROS1 gene rearrangement / fusion and / or drug-resistant mutation; preferably, the tumor is a solid tumor or a blood tumor; further preferably, the tumor is a solid tumor.
[0097] According to an embodiment of the present invention, the NTRK resistance mutation is NTRK1-G595R, NTRK1-G667C, NTRK3-G623R or NTRK3-G696A; preferably, the NTRK resistance mutation is NTRK1-G595R, NTRK1-G667C or NTRK3-G623R; further preferably, the NTRK resistance mutation is NTRK1-G595R or NTRK1-G667C.
[0098] In one embodiment, the above-mentioned TRK-mediated disease is selected from diseases mediated by one, two or three of TRKA, TRKB or TRKC.
[0099] In one embodiment, the above-mentioned disease involves NTRK gene, TRK protein, or disordered expression, activity or level thereof; preferably, involves NTRK gene fusion, amplification, rearrangement, mutation or high expression; further preferably, involves NTRK gene fusion or mutation.
[0100] According to an embodiment of the present invention, the NTRK mutation is NTRK1-G595R, NTRK1-G667C, NTRK3-G623R or NTRK3-G696A; preferably, the NTRK resistance mutation is NTRK1-G595R, NTRK1-G667C or NTRK3-G623R; further preferably, the NTRK resistance mutation is NTRK1-G595R or NTRK1-G667C.
[0101] In one embodiment, the above-mentioned disease involves ROS1 gene, ROS1 protein, or disordered expression, activity or level thereof; preferably, involves ROS1 gene fusion, amplification, rearrangement, mutation or high expression; further preferably, involves ROS1 gene rearrangement / fusion or mutation.
[0102] In one embodiment, the above-mentioned disease involves one or more genes, proteins, or dysregulation of their expression, activity or level among TRK, ALK, and ROS1; preferably, it involves one or more gene fusion, amplification, rearrangement, mutation or high expression among NTRK, ALK, and ROS1; further preferably, it involves one or more gene rearrangement / fusion or mutation among NTRK, ALK, and ROS1.
[0103] In one embodiment, the cell proliferative disease is a tumor or cancer.
[0104] In one embodiment, the above-mentioned tumor or cancer is a solid tumor and a blood tumor; preferably a solid tumor; further preferably a solid tumor positive for NTRK gene rearrangement / fusion and / or drug-resistant mutation, or a solid tumor positive for ROS1 gene rearrangement / fusion and / or drug-resistant mutation.
[0105] According to an embodiment of the present invention, the NTRK resistance mutation is NTRK1-G595R, NTRK1-G667C, NTRK3-G623R or NTRK3-G696A; preferably, the NTRK resistance mutation is NTRK1-G595R, NTRK1-G667C or NTRK3-G623R; further preferably, the NTRK resistance mutation is NTRK1-G595R or NTRK1-G667C.
[0106] In one embodiment, the tumor or cancer is a hematological malignancy, lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, glioma, colorectal cancer, melanoma, cancer of the head and neck, gallbladder cancer, thyroid cancer, malignant glioma, gastric cancer, neuroblastoma or salivary gland cancer; preferably, the lung cancer is non-small cell lung cancer.
[0107] According to an embodiment of the present invention, the present invention provides a method for preparing a salt of a compound represented by formula (A-1), comprising reacting a compound represented by formula (A) with an acid in a reaction solvent, and separating to obtain a salt of the compound represented by formula (A-1):
[0108]
[0109] in,
[0110] HA is selected from the acids defined above. The acid is preferably hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid or benzenesulfonic acid; more preferably hydrochloric acid, sulfuric acid or methanesulfonic acid; more preferably hydrochloric acid or sulfuric acid;
[0111] n is an integer or half integer of 1 / 2 to 4; preferably an integer or half integer of 1 / 2 to 3; more preferably 0.5, 1, 1.5 or 2.
[0112] According to the preparation method of the present invention, the molar ratio of the compound represented by formula (A) to the acid is 1-2:0.5-2, preferably 1:0.6-1.1.
[0113] According to the preparation method of the present invention, the reaction temperature is 0 to 70°C, preferably 5 to 60°C, and more preferably room temperature to 50°C.
[0114] According to the preparation method of the present invention, the reaction solvent is selected from one or a combination of two of alcohols, esters, nitriles, ketones, water or heterocyclic hydrocarbon solvents; preferably ROH, RCOOR 1 , RCN, RCOR 1 , water or heterocyclic alkane solvents, or a combination of two thereof, wherein R and R 1 Each independently selected from C 1-6 Straight or branched alkyl; preferably, R and R 1 Each independently selected from C 1-4 Straight-chain or branched alkyl; preferably, the reaction solvent is selected from one or a combination of two of methanol, ethanol, ethyl acetate, acetone, butanone, acetonitrile, water or tetrahydrofuran; when it is a mixed solvent composed of two solvents, the volume ratio of the two solvents is 1-10:10-1, preferably 1-5:5-1, and further preferably 1-3:3-1.
[0115] According to the preparation method of the present invention, after the reaction is completed, the temperature is lowered to 0-30°C, and the mixture is allowed to stand for crystallization for 0.5-24 hours, and the solid is separated and dried to obtain the salt of the compound represented by formula (A-1). Preferably, the crystallization temperature is room temperature and the crystallization time is 1-20 hours.
[0116] According to the preparation method of the present invention, the separation step comprises separating the obtained salt of the compound represented by formula (A-1) from the crystal solution by using a suitable method such as suction filtration, filtration, centrifugation, etc.
[0117] According to the preparation method of the present invention, the drying method can be any suitable known method, preferably drying at room temperature or drying at 50°C. The specific drying conditions are, for example, preferably a drying time of 1 to 50 hours, more preferably 3 to 24 hours. Regardless of the drying method used, it is preferred that the residual solvent content in the obtained product meets the quality standards.
[0118] Definition and Description
[0119] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be considered ambiguous or unclear without special definition, but should be understood according to the ordinary meaning.
[0120] The term "half integer" refers to a number having the form (2m+1) / 2, wherein m is selected from a natural number that conforms to the numerical range described in the context. For example, when n is a half integer of 1 / 2 to 4, m in the above formula can be selected from 0, 1, 2 or 3.
[0121] The “crystalline salt of the compound represented by formula (A-1)”, “crystalline hydrochloride of the compound represented by formula (1-1)”, “crystalline sulfate of the compound represented by formula (2-1)” or “crystalline methanesulfonate of the compound represented by formula (3-1)” mentioned in the context of this application refer to the salt of the compound represented by formula (A-1) in crystalline form, the hydrochloride of the compound represented by formula (1-1), the sulfate of the compound represented by formula (2-1) or the methanesulfonate of the compound represented by formula (3-1), including the salt of the compound represented by formula (A-1), the hydrochloride of the compound represented by formula (1-1), the sulfate of the compound represented by formula (2-1) or the methanesulfonate of the compound represented by formula (3-1) in anhydrous and solvent-free form, hydrate form or solvate form.
[0122] The term "solvate" or "solvate" refers to an association formed by a stoichiometric or non-stoichiometric ratio of solvent molecules and a salt of the compound represented by formula (A-1) of the present application, a hydrochloride of the compound represented by formula (1-1), a sulfate of the compound represented by formula (2-1) or a methanesulfonate of the compound represented by formula (3-1), including associations containing both water molecules and one or more other solvent molecules, and associations containing only one or more other solvent molecules.
[0123] The term "hydrate" refers to an association formed by a stoichiometric or non-stoichiometric ratio of water molecules and a salt of the compound represented by formula (A-1) of the present application, a hydrochloride of the compound represented by formula (1-1), a sulfate of the compound represented by formula (2-1), or a methanesulfonate of the compound represented by formula (3-1).
[0124] The "anhydrous and solvent-free form" means that it does not contain water molecules or solvent molecules, or water molecules or solvent molecules coexist with the salt of the compound represented by formula (A-1), the hydrochloride of the compound represented by formula (1-1), the sulfate of the compound represented by formula (2-1) or the methanesulfonate of the compound represented by formula (3-1) in a manner that is bound by non-intermolecular forces, such as by adsorption.
[0125] The "room temperature" is the room temperature conventionally known in the art, generally 10-30°C, preferably 25°C±5°C, such as 20°C, 25°C, or 30°C.
[0126] In the X-ray powder diffraction pattern, the term "substantially" or "substantially as shown" refers to a substantially pure crystalline form, in which at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% of the peaks in the powder X-ray diffraction pattern appear in the given pattern. Further, when the content of a certain crystalline form in the product gradually decreases, some of the diffraction peaks in its X-ray powder diffraction pattern attributable to the crystalline form may become less due to the detection sensitivity of the instrument. In addition, for any given crystalline form, there may be slight errors in the position of the peak, which is also well known in the field of crystallography. For example, due to changes in temperature, sample movement or instrument calibration during sample analysis, the position of the peak can move, and the measurement error of the 2θ value is sometimes about ±0.3°, usually about ±0.2°. Therefore, when determining each crystalline structure, this error should be taken into account, and the term "substantially" or "substantially as shown in the accompanying drawings" is also intended to cover such differences in the diffraction peak positions, referring to ±0.3°, preferably ±0.2°.
[0127] In a DSC spectrum or a TGA spectrum, the term "substantially" or "substantially as shown in the figure" means that for the same crystal form of the same compound, in consecutive analyses, the error of the thermal transition onset temperature, the peak temperature of the endothermic peak, the peak temperature of the exothermic peak, the melting point, the starting temperature of weight loss or the end temperature of weight loss is typically within about 5°C, usually within about 3°C. When describing a compound as having a given thermal transition onset temperature, peak temperature of the endothermic peak, peak temperature of the exothermic peak, the melting point, the starting temperature of weight loss or the end temperature of weight loss, it refers to the temperature ±5°C.
[0128] As used herein, the term "cell proliferative disorder" refers to a condition in which a population of cells grows at a rate that is slower or faster than expected under given physiological conditions and circumstances.
[0129] The term "tumor" includes benign tumors, malignant tumors and borderline tumors, among which malignant tumors are collectively referred to as cancer.
[0130] As used herein, the term "prevent" or "preventing" means that when used for a disease or condition (e.g., cancer), the compound or drug (e.g., the combination product claimed herein) can reduce the frequency of symptoms of the medical condition in a subject or delay its onset compared to a subject to which the compound or drug (e.g., the combination product claimed herein) is not administered.
[0131] As used herein, the term "treat," "treat," "treat," "treat," or "treat" refers to alleviating, relieving, or ameliorating symptoms of a disease or condition, ameliorating underlying metabolically caused symptoms, inhibiting a disease or symptom, such as arresting the development of a disease or condition, alleviating a disease or condition, causing regression of a disease or condition, alleviating a condition caused by a disease or condition, or arresting symptoms of a disease or condition.
[0132] The term "pharmaceutically acceptable carrier", also known as "pharmaceutically acceptable excipient" refers to those carriers or excipients that have no significant irritation to the organism and will not impair the biological activity and performance of the active compound.
[0133] The intermediate compounds of the present application can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitution methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.
[0134] The chemical reactions of the specific embodiments of the present application are carried out in a suitable solvent, which must be suitable for the chemical changes of the present application and the reagents and materials required. In order to obtain the compounds of the present application, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments.
[0135] The present application will be described in detail below through examples, which do not imply any limitation to the present application.
[0136] All solvents used in this application were commercially available and used without further purification.
[0137] Technical Effects
[0138] The salt of the compound represented by formula (A-1), the salt of the compound represented by formula (A-1) in crystalline form, and the specific salt form and crystal form thereof provided by the present invention have one or more of the following beneficial effects:
[0139] (1) The salt of the compound represented by formula (A-1) is easy to prepare, purify and isolate, and has a high purity of >98%;
[0140] (2) The salt of the compound represented by formula (A-1) in crystalline form has good crystallinity, such as the crystalline form I of the hydrochloride represented by formula (1-1), the crystalline form I of the sulfate represented by formula (2-1), the crystalline form II of the sulfate represented by formula (2-1), and the methanesulfonate represented by formula (3-1);
[0141] (3) Preferably, the salt and its crystal form have good physical and chemical stability and good medicinal prospects;
[0142] (4) In vitro kinase activity inhibition tests show that the compound represented by formula (A) exhibits excellent inhibitory activity against a variety of kinases (such as TRK, ALK, ROS1) and their mutants, especially TRK and its mutant forms. On this basis, the development of the salt (A-1) of the compound represented by formula (A) has good application prospects;
[0143] (5) In vitro cell inhibitory activity tests showed that the compound represented by formula (A) had a strong inhibitory effect on cells with multiple TRK mutations, and had an IC inhibitory activity of 1.1% against 6 types of cells. 50 Below 10 nM, preferably below 5 nM, and more preferably below 1 nM;
[0144] (6) The results of the in vivo tumor inhibition test showed that compared with the control compound, the compound represented by formula (A) had better in vivo anti-tumor effect, better tolerance, and higher drugability;
[0145] (7) In vivo mechanism studies have shown that the compound represented by formula (A) can inhibit TRK phosphorylation in tumor tissues, thereby effectively inhibiting the phosphorylation of PLCγ1 and AKT, and inhibiting the growth of tumor tissues. BRIEF DESCRIPTION OF THE DRAWINGS
[0146] Figure 1 : X-ray powder diffraction pattern of Form I of the hydrochloride salt of Example 1.
[0147] Figure 2 : DSC-TGA spectrum of the crystalline form I of the hydrochloride salt of Example 1.
[0148] Figure 3 : X-ray powder diffraction pattern of Form I of the sulfate of Example 2.
[0149] Figure 4 : DSC-TGA spectrum of Form I of the sulfate of Example 2.
[0150] Figure 5: X-ray powder diffraction pattern of Form II of the sulfate of Example 3.
[0151] Figure 6 : DSC-TGA spectrum of Form II of the sulfate salt of Example 3.
[0152] Figure 7 : X-ray powder diffraction pattern of Form I of the mesylate salt of Example 4.
[0153] Figure 8 : DSC-TGA spectrum of Form I of the mesylate salt of Example 4.
[0154] Fig. 9 : Result diagram of test example 4. DETAILED DESCRIPTION
[0155] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0156] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0157] 1. X-ray powder diffractometer (XRPD)
[0158] Instrument model: Bruker D8 Advance X-ray powder diffractometer
[0159] Test method: About 5-20 mg of sample is used for XRPD detection
[0160] The detailed XRPD parameters are as follows:
[0161] X-ray generator: Cu, Kα,
[0162] Light tube voltage: 40kV, light tube current: 40mA
[0163] Scanning range: 3°-40°(2θ)
[0164] Scanning step: 0.02°
[0165] Sample pan: Zero background sample pan.
[0166] 2. Differential Scanning Calorimeter (DSC)
[0167] Instrument model: TA Q200 differential scanning calorimeter
[0168] Test method: Place the sample in a perforated aluminum crucible, equilibrate the sample at 25°C, and heat it to the final temperature at a heating rate of 10°C / min.
[0169] Sample amount: 1~3mg
[0170] Air flow type: Nitrogen
[0171] Flow rate: 50mL / min
[0172] Heating start temperature: 25°C
[0173] Termination temperature: 300℃.
[0174] 3. Thermogravimetric analysis (TGA)
[0175] Instrument model: TA Q500 thermogravimetric analyzer (TA, US)
[0176] Test method: Place the sample in a pre-peeled aluminum crucible. After the sample mass is automatically weighed in the TGA heating furnace, heat the sample to the final temperature at a rate of 10°C / min.
[0177] Sample size: 1-5 mg
[0178] Air flow type: Nitrogen
[0179] Sample chamber air flow rate: 25mL / min
[0180] Heating starting temperature: room temperature
[0181] Termination temperature: 300℃.
[0182] 4. Dynamic moisture sorption and desorption analysis (DVS)
[0183] Instrument model: DVS Intrinsic dynamic water vapor sorption instrument (SMS)
[0184] Test method: Place a sufficient amount of sample (10-20 mg) in a pre-peeled sample chamber and weigh automatically. Dry the sample at 40°C (only for anhydrous substances, start at 25°C for hydrates) until dm / dt is less than 0.002%. Cool to 25°C and start the test using the operating parameters in the table below.
[0185] Stage time 60 minutes Drying / testing temperature 40℃ / 25℃ cycle The whole cycle Each RH balance time 1 hour Data storage rate 5 seconds Total airflow 200sccm Total gas flow rate after the experiment 200sccm
[0186] 5. High Performance Liquid Chromatography (HPLC)
[0187] Instrument model: Agilent 1260 series (Waters, US)
[0188] Chromatographic column: Express C18 4.6x 100mm, 2.7μm
[0189] Test conditions: wavelength 248nm; column temperature 40℃
[0190] Flow rate: 1.0mL / min
[0191] Injection volume: 5 μL.
[0192] 6. Nuclear Magnetic Resonance Spectroscopy (NMRS)
[0193] Instrument model: Bruker AVANCE III 400 (Bruker, GER)
[0194] Content and test solvent: 1 H-NMR, the test solvent was DMSO-d6.
[0195] Abbreviations: DCM: dichloromethane; DIPEA: diisopropylethylamine; DMF: N,N-dimethylformamide; EA: ethyl acetate; PE: petroleum ether; DMSO: dimethyl sulfoxide; TBTU: O-benzotriazol-N,N,N',N'-tetramethyluronium tetrafluoroborate; BOP: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate; ATP: adenosine 5'-triphosphate; DTT: 1,4-dithiothreitol; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium blue bromide.
[0196] Preparation Example 1: Preparation of the compound of formula (A)
[0197]
[0198] Step a: A mixed solution of (2R, 4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidine (5.826 g, 28.958 mmol), 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (6.534 g, 28.958 mmol), n-butanol (50 mL) and diisopropylamine (8.790 g, 86.874 mmol) was reacted at 100°C for 4 h, and concentrated under reduced pressure to obtain a crude product of 5-((2R, 4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (B1). The crude product was used directly in the next step without purification. (ES, m / z): 391.05 [M+H] + .
[0199] Step b: Dissolve the crude product of ethyl 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate in anhydrous ethanol (50 mL), stir at 75°C until the system is clear and transparent, then add LiOH (4.86 g, 115.832 mmol) aqueous solution (50 mL), stir at 75°C for 5 h. After cooling to room temperature, concentrate under reduced pressure to remove anhydrous ethanol. Slowly add 1N HCl aqueous solution to adjust pH 3 to 4, and a large amount of white solid precipitates. Stir at room temperature for 30 minutes and then filter, and wash the filter cake with a small amount of purified water. Collect the filter cake, dry it and weigh it to obtain a white powder solid 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (9.9 g). The filtrate was extracted with EA (2×50 mL), the organic phases were combined, washed with water (2×50 mL) and saturated aqueous NaCl solution (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Column chromatography purification (PE:EA=4:1-2:1, v / v) was performed, the product spots were collected, and concentrated under reduced pressure to obtain a white powdery solid 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (386 mg). A total of 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid pure product (B2, 10.286 g, 98%) was obtained, (ES, m / z): 363.04 [M+H] + .
[0200] Step c: Add 1-Boc-4-(4-aminophenyl)piperazine (918 mg, 3.312 mmol) to a solution of 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (Intermediate B2, 1000 mg, 2.76 mmol) and TBTU (1063 mg, 3.312 mmol) in anhydrous DMF (10 mL), then add DIPEA (1284 mg, 9.936 mmol) dropwise at 0°C and react at room temperature overnight. The reaction solution was added with water (50 mL) and mixed and stirred. Solid precipitated. The filter cake was obtained by vacuum filtration and dried in a vacuum oven to obtain tert-butyl 4-(4-(5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)phenylpiperazine-1-carboxylate (B3, 1320 mg, 77%). (ES, m / z): 622.09 [M+H] + .
[0201] Step d: DCM and CF3COOH (12 mL, 3 / 1, v / v) were added to tert-butyl 4-(4-(5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamido)phenylpiperazine-1-carboxylate (1.320 g, 2.125 mmol), and the mixture was stirred at room temperature for 4 h. The reaction solution was concentrated under reduced pressure, and water (80 mL) and EA were added to the residue. (10mL), adjusted the base with ammonia water (pH = 9), stirred to precipitate solid, filtered under reduced pressure to obtain a filter cake, rinsed with a small amount of water, and weighed after drying to obtain 5-((2R, 4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)-N-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (B4, 907 mg, 82%), (ES, m / z): 522.09 [M+H] + .
[0202] Step e: Hydroxyacetic acid (306 mg, 4.026 mmol) was added to a solution of 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)-N-(4-(piperazine-4-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Intermediate B4, 700 mg, 1.342 mmol) and BOP (712 mg, 1.610 mmol) in anhydrous DMF (10 mL), and then DIPEA (520 mg, 4.026 mmol) was added dropwise at 0°C and the reaction was stirred at room temperature for 4 h. The reaction solution was added with water (80 mL) and mixed, and the mixture was extracted with EA (55 mL×2), and the combined organic phase was washed with H2O (80 mL) and brine (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and eluted with a column chromatography silica gel column, first with 1% (v / v) MeOH-DCM and then with 2% (v / v) MeOH-DCM. The product spots were collected and concentrated to give 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)-N-(4-(4-(2-hydroxyacetyl)piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (A, 666 mg, 86%), (ES, m / z): 580.14 [M+H] + . 1 H NMR(600MHz,DMSO-d6)δ9.810(s,1H),8.906-8.723(m,1H),8.283-8.229(m,1H),7 .623(s,1H),7.343(s,1H),7.210(s,2H),7.061-6.842(m,4H),5.711-5.495(m,2H ),4.631(t,J=5.4Hz,1H),4.556-4.548(m,1H),4.318-4.225(m,1H),4.150(d,J=5 .4Hz, 2H), 3.637(s,2H), 3.513(s,2H), 3.124-3.106(m,4H), 2.957-2.912(m,1H).
[0203] Reference substance preparation example 1-5:
[0204] In addition: Compounds D1 to D5 were prepared with reference to the preparation process routes and operations in WO2019029629A1 and WO2012034095A1.
[0205]
[0206] Example 1: Preparation of Form I of the hydrochloride salt represented by formula (1-1)
[0207] At room temperature, weigh the compound sample (301.9 mg) of Formula (A) of Preparation Example 1 into a reaction bottle, add a mixed solution of ethyl acetate and methanol (6.04 mL, v / v = 1 / 2), add hydrochloric acid (1.1 eq) dropwise to the system, stir at room temperature for 18 hours, and filter to obtain a solid. The obtained solid was dried at 50°C for 4 hours to obtain 202.3 mg of solid, with a yield of 63%. After testing, it was confirmed that the salt had been formed, and the base / acid ratio was 1:1, to obtain the hydrochloride shown in Formula (1-1).
[0208] The sample was taken for X-ray powder diffraction, which showed a crystalline solid (form I) with good crystallinity. Figure 1 The XRPD diffraction peak data are shown in Table 1. The sample was taken for DSC-TGA test. The DSC graph showed endothermic peaks at 62.61℃, 119.14℃ and 174.70℃. The TGA graph showed that the sample had a weight loss of 1.5910% between room temperature and 50℃, a weight loss of 1.9155% between 50℃ and 120℃, and a weight loss of 3.2847% between 120℃ and 170℃. Figure 2 .
[0209] Table 1 XRPD diffraction peak data of the hydrochloride crystal form I shown in formula (1-1)
[0210] Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % 5.811 30.8 15.229 24.4 24.045 12.2 6.399 19.7 16.107 7.9 24.775 11.0 7.579 19.8 17.240 100.0 25.485 7.6 11.693 30.5 19.230 38.5 25.890 10.2 12.824 15.1 22.912 11.7
[0211] Note: Peaks with relative peak intensity > 7.0% are selected and listed in the table.
[0212] Example 2: Preparation of Crystalline Form I of Sulfate Represented by Formula (2-1)
[0213] At room temperature, a sample of the compound of formula (A) of Preparation Example 1 (about 30 mg) was weighed into a reaction bottle, and a mixed solution of acetonitrile and methanol (0.8 mL, v / v = 1 / 1) was added, and a methanol solution of sulfuric acid (1 mol / L, 0.6 eq) was added dropwise to the system, and the mixture was stirred at room temperature for 14 hours, and a solid was obtained by filtration. After the obtained solid was dried for 4 days at room temperature and under nitrogen atmosphere, it was confirmed that a salt had been formed, and the base / acid ratio was 1:0.5, and the sulfate represented by formula (2-1) was obtained.
[0214] The sample was taken for X-ray powder diffraction, which showed a crystalline solid (form I) with good crystallinity. Figure 3 The XRPD diffraction peak data are shown in Table 2. The sample was taken for DSC-TGA test. The DSC graph showed endothermic peaks at 235°C and 241°C. Figure 4 .
[0215] Table 2 XRPD diffraction peak data of the crystal form I of the sulfate represented by formula (2-1)
[0216] Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % 5.671 21.0 18.893 66.1 26.128 11.8 7.751 56.3 19.375 24.5 26.883 7.2 9.129 7.0 19.746 100.0 28.826 5.4 11.486 4.5 20.543 13.1 29.155 7.1 12.211 8.5 21.109 6.0 29.856 4.1 12.532 20.3 21.798 8.6 31.689 11.0 12.935 9.3 23.069 11.3 32.084 7.8 14.628 4.1 23.604 23.4 33.853 10.1 15.947 6.2 24.592 31.6 17.451 70.9 25.323 15.2
[0217] Note: Peaks with relative peak intensity > 4.0% are selected and listed in the table.
[0218] Example 3: Preparation of Crystalline Form II of Sulfate Represented by Formula (2-1)
[0219] At room temperature, weigh the compound sample (502.1 mg) of Formula (A) of Preparation Example 1 into a reaction bottle, add a mixed solution of acetone and ethyl acetate (10 v, v / v = 1 / 1, 5 mL), add a methanol solution of sulfuric acid (1 mol / L, 1.1 eq) dropwise to the system, stir at 50 ° C for 3 hours, cool to room temperature and continue stirring for 14 hours, and filter to obtain a solid. The obtained solid was dried at 50 ° C for 16 hours to obtain 409.2 mg of solid, with a yield of 69.7%. After testing, it was confirmed that the salt had been formed, and the base / acid ratio was 1:0.5, and the sulfate shown in formula (2-1) was obtained.
[0220] The sample was taken for X-ray powder diffraction, which showed a crystalline solid (form II) with good crystallinity. Figure 5 The XRPD diffraction peak data are shown in Table 3. The sample was taken for DSC-TGA test. The DSC graph showed an endothermic peak at 227.22°C. Figure 6 .
[0221] Table 3 XRPD diffraction peak data of the crystal form II of the sulfate represented by formula (2-1)
[0222] Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % 3.866 18.1 12.565 14.6 21.757 7.8 5.456 100.0 16.001 26.0 22.347 7.0 7.609 28.1 16.512 41.9 22.748 10.2 8.650 9.6 17.274 9.7 23.440 6.5 8.932 6.6 18.524 28.0 24.859 7.4 10.911 15.9 18.921 80.4 25.362 9.7 12.263 6.8 19.355 17.7 25.853 7.1
[0223] Note: Peaks with relative peak intensity > 6.0% are selected and listed in the table.
[0224] Example 4: Preparation of Form I of the Methanesulfonate Salt of Formula (3-1)
[0225] At room temperature, weigh a sample of the compound of formula (A) of Preparation Example 1 (about 30 mg) into a reaction bottle, add methanol (0.5 mL), add methanesulfonic acid (1.1 eq) dropwise to the system, stir at 50°C for 1 hour, then continue stirring at room temperature for 3 hours, and filter to obtain a solid. After the obtained solid was dried at 50°C for 15 hours, it was confirmed that it had formed a salt, and the base / acid ratio was 1:1, to obtain the methanesulfonate shown in formula (3-1).
[0226] The sample was taken for X-ray powder diffraction, which showed a crystalline solid (form I) with good crystallinity. Figure 7The XRPD diffraction peak data are shown in Table 4. The sample was taken for DSC-TGA test. The DSC graph showed that there were endothermic peaks at 71.95℃ and 180.62℃. The TGA graph showed that the sample had a weight loss of 1.9565% between room temperature and 100℃, and a weight loss of 1.1072% between 100 and 200℃. Figure 8 .
[0227] Table 4 XRPD diffraction peak data of the crystal form I of the mesylate represented by formula (3-1)
[0228] Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % Peak position (2θ)° Relative Strength % 5.388 9.7 15.480 14.7 20.187 7.4 5.879 6.2 15.917 6.6 21.118 11.9 6.356 7.2 16.092 10.5 21.925 9.2 6.816 100.0 17.748 5.3 25.951 13.8 8.145 15.2 18.023 13.5 26.268 19.7 10.558 29.1 18.898 15.5 11.917 15.2 19.385 12.3
[0229] Note: Peaks with relative peak intensity > 5.0% are selected and listed in the table.
[0230] Example 5: Preparation of p-toluenesulfonate
[0231] At room temperature, a sample of the compound of formula (A) of Preparation Example 1 (about 30 mg) was weighed into a reaction bottle, acetonitrile (0.5 mL) was added, p-toluenesulfonic acid (1.1 eq) was added dropwise to the system, stirred at room temperature for 3 hours, and filtered to obtain a solid. The obtained solid was dried at 50° C. for 15 hours, and after testing, it was confirmed that the solid had formed a salt.
[0232] A sample was taken for X-ray powder diffraction, which showed that it was almost amorphous.
[0233] Example 6: Preparation of benzenesulfonate
[0234] The benzenesulfonate salt was prepared by a method similar to that of Example 5. A sample was taken for X-ray powder diffraction, which showed that it was almost amorphous.
[0235] Comparative Example 1: Preparation of maleate, succinate, malate, citrate, fumarate and tartrate
[0236] An appropriate amount of maleic acid, succinic acid, malic acid, citric acid, fumaric acid or tartaric acid was dissolved in methanol to prepare an acid solution with a concentration of 0.1 M; a sample of the compound of formula (A) obtained in Preparation Example 1 (about 300 mg) was dissolved in a mixed solution of dichloromethane and methanol (10 mL, v / v=1 / 1) to make the concentration of the compound of formula (A) in the solution reach 30 mg / mL.
[0237] The above solution of the compound of formula (A) was added to the well plate (100 μL per well), followed by the above prepared acid solution (1.1 eq), and after the solvent in the well plate was completely evaporated at room temperature, 200 μL of the selected solvent listed in the following table was added to each well, the well plate was sealed with a sealing film, and then the well was punctured, and then the solvent was slowly evaporated. The results are shown in Table 5.
[0238] Table 5 Salt-forming reaction results
[0239] Maleic acid Succinic acid Malic Acid Citric Acid Fumaric Acid tartaric acid Methanol Oil Oil Oil G G G Isopropyl alcohol Oil Oil Oil G G G Tetrahydrofuran Oil G G Oil Oil Oil Acetonitrile Oil G G Oil Oil Oil Methyl tert-butyl ether Oil G G G G Oil acetone Oil G G G G Oil water Oil Oil Oil G G G Ethyl acetate Oil Oil Oil G G G
[0240] Note: Oil stands for oily substance; G stands for glassy state.
[0241] The results showed that no solid was precipitated in the reaction system. Further, after the solvent was evaporated, the samples obtained after the six acids reacted with the compound of formula (A) were all in the form of oil or glass.
[0242] Test Example 1: Solid Stability Test of Different Crystal Forms of Compound (A-1)
[0243] Weigh appropriate amounts of samples of Example 1 (Form I of hydrochloride) and Example 3 (Form II of sulfate) into vials, place them under high temperature (60°C, sealed) and accelerated (40°C / 75%RH, open) conditions for 7 days, respectively, take samples for purity detection and X-ray powder diffraction, and examine the stability of Example 1 (Form I of hydrochloride) and Example 3 (Form II of sulfate) under different conditions. The results are shown in Table 6.
[0244] Table 6 Solid stability test results
[0245]
[0246] Note: / indicates not tested.
[0247] The data show that Example 1 (crystalline form I of the hydrochloride salt) and Example 3 (crystalline form II of the sulfate salt) can both maintain chemical stability and crystalline stability in the solid stability test.
[0248] Test Example 2: DVS test of Example 3 (Form II of sulfate)
[0249] The sample of Example 3 (crystalline form II of sulfate) was placed in the DVS sample chamber for testing. The sample after DVS was subjected to X-ray powder diffraction, and the results are shown in Table 7.
[0250] Table 7 DVS test results of Example 3 (Form II of sulfate)
[0251] Examples and initial crystal form Crystalline form after DVS Example 3 (Crystalline Form II of Sulfate) Crystal form unchanged
[0252] The data show that the crystal form of the sample of Example 3 (crystal form II of sulfate) remains unchanged after the DVS test.
[0253] Test Example 1: TRK kinase inhibition test
[0254] 1. Operation steps:
[0255] 1.1 Kinase reaction:
[0256] Add a certain concentration gradient of the test compound and enzyme solution (add kinase buffer (1X kinase buffer (Cisbio, Cat#62EZBFDD), pH 7.5; 5mM MgCl2, 1mM DTT)) to the compound plate in sequence, and centrifuge at 1000rpm for 30 seconds. Seal the plate and incubate the plate in a constant temperature incubator at 25°C for 30 minutes. Prepare substrate solutions of TK-Sub-biotin (Cisbio, Cat#61TKOBL) and ATP (Sigma, Cat#R0441), add the substrate mixture solution to the 384-well plate, and centrifuge at 1000rpm for 30 seconds. Seal the plate and incubate the plate in a constant temperature incubator at 25°C for 60 minutes.
[0257]
[0258] 1.2 Kinase assay:
[0259] Dilute and mix TK antibody and XL665 and add to the assay plate. Centrifuge at 1000rpm for 30 seconds. Seal the plate and incubate it in a 25℃ incubator for 60 minutes. Place the assay plate on the Envision machine for reading. (HTRF 665 / 615 ratio: 665nm signal value / 615nm signal value)
[0260] Inhibition rate = (ratio 阴性对照孔 -ratio 化合物孔 ) / (ratio 阴性对照孔 -ratio 无酶对照孔 )×100%
[0261] 1.3 Data analysis and curve fitting
[0262] Fitting data to obtain IC in XLFit excel addin version 5.4.0.8 50 value.
[0263] 1.4QC parameters
[0264] Reference compounds were included in each plate and their IC 50 Each time is within 3 times.
[0265] 2. Test results: as shown in Table 8
[0266] Table 8 Kinase inhibitory activity of different tested compounds on TRK
[0267]
[0268]
[0269] Note: RXDX-101, LOXO-195 and LOXO-101 are all publicly known compounds and are commercially available as marketed products (pharmaceutical or chemical grade products); Compound represented by formula (A): Sample of Preparation Example 1.
[0270] The results show that the compound represented by formula (A) exhibits high kinase inhibitory activity in multiple kinases, and its activity in TRKA, TRKB, TRKC and TRKC-G696A is better than that of RXDX-101, LOXO-101, and LOXO-195 or equivalent; and its inhibitory activity in multiple mutant resistant kinases (G595R, G667C, G623R) is significantly better than that of RXDX-101, LOXO-195 and LOXO-101.
[0271] Test Example 2: ALK and ROS1 kinase inhibition test
[0272] 1. Operation steps:
[0273] 1.1 Kinase reaction:
[0274] The compound was diluted with DMSO to a certain concentration and then diluted 4 times in a gradient. A certain concentration of compound, enzyme solution and DMSO were added to a 384-well plate and incubated at room temperature for 10 minutes; fluorescein-labeled peptide and ATP (sigma, Cat. No.: A7699-1G, Lot No.: 987-65-5) were added and incubated at 28°C for a certain period of time; stop solution was added and the reading was taken.
[0275] The inhibition rate formula corresponding to a single concentration is: Inhibition rate = (OD 阴性对照孔 -OD 化合物孔 ) / (OD 阴性对照孔 -OD 无酶对照孔 )×100%
[0276]
[0277] 1.2 Data analysis and curve fitting
[0278] Fitting data to obtain IC in XLFit excel add-in version 4.3.1 50 The results are shown in Table 9.
[0279] Table 9 Inhibitory activity of different compounds on ALK and ROS1 kinases
[0280]
[0281] Note: Compound represented by formula (A): Sample of Preparation Example 1.
[0282] The results showed that the compound represented by formula (A) exhibited strong inhibitory activity in ROS1 kinase, which was significantly better than RXDX-101 and LOXO-101, and better than LOXO-195; it also had good inhibitory activity against ALK kinase, which was significantly better than LOXO-101 and LOXO-195.
[0283] Test Example 3: In vitro cell inhibition test
[0284] 1. Cell lines
[0285] 6 experimental cell lines from: Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd.
[0286] Cell type: Murine B cells
[0287] Culture medium: RPMI-1640 + 10% FBS
[0288] 2. Test methods
[0289] Cells in the logarithmic growth phase were harvested and counted using a platelet counter. Cell suspensions of a certain density were evenly inoculated in a 96-well plate, 100 μL per well, and shaken to disperse evenly into the wells; 100 μL of a drug solution with a certain concentration gradient was added to each well, and three replicate wells were set for each drug concentration; cultured in a 37°C CO2 incubator for 72 hours; MTT working solution (5 mg / mL) was added, 20 μL per well; acted at 37°C for 4 hours; centrifuged in a plate centrifuge at 1000 rpm / min for 5 minutes, 180 μL of the culture medium was aspirated and 150 μL of DMSO was added, the microporous oscillator was shaken to mix, the bottom of the plate was wiped clean, and the optical density (OD) was detected at 550 nm by an ELISA reader.
[0290] 3. Data Analysis
[0291] Inhibition rate = (control well OD - test well OD) / (control well OD - blank well OD) * 100%. According to the inhibition rate of each concentration, the half inhibition concentration IC was calculated using SPSS software. 50 value.
[0292] 4. Test results: The results are shown in Table 10 and Table 11:
[0293] Table 10 Inhibitory activity of different compounds on different cell lines
[0294]
[0295]
[0296] Note: Compound represented by formula (A): Sample of Preparation Example 1.
[0297] Table 11 Inhibitory activity of control compounds on different cell lines
[0298]
[0299] The results show that the compound represented by formula (A) exhibits good in vitro cell activity in a variety of wild-type and mutant drug-resistant cell lines, and is significantly better than RXDX-101, LOXO-195, LOXO-101 and prior art compounds D1-D5.
[0300] Experimental Example 4: Study on the in vivo mechanism of the compound represented by formula (A)
[0301] 1. Test methods
[0302] 1.1 Model preparation:
[0303] Take the mutant drug-resistant cells Ba / F3 LMNA-NTRK1-G595R in the logarithmic growth phase, collect them, and resuspend them in serum-free medium to a cell concentration of 6×10 7 -10×10 7 / mL, and add an equal volume of Matrigel to the cell suspension to make the final concentration of cells 3×10 7 -5×10 7 NuNu mice (Beijing Weitong Lihua, 4-6 weeks old, female) were subcutaneously inoculated with 0.1 mL of tumor cell suspension in the axilla of the forelimb, with an inoculation volume of 3×10 6 -5×10 6 To prepare the animal model.
[0304] 1.2 Experimental Grouping:
[0305] The maximum and minimum tumor diameters of the nude mouse transplanted tumor were measured with a vernier caliper to calculate the tumor volume: The calculation formula for tumor volume (TV) is: V = 1 / 2 × a × b 2 , where a and b represent the maximum and minimum diameters of the tumor, respectively. Nude mice with appropriate tumor volumes were selected and randomly divided into 7 groups (200-300 mm 3 ), 3 in each group.
[0306] 1.3 Administration
[0307] The drug was administered orally according to the animal body weight, with a dosage volume of 10 ml / kg. The compound represented by formula (A) was prepared into the required dosage concentration using "3% DMSO + 96% HP-β-CD (0.5 g / mL) + 1% HCL".
[0308] The control group had three rats, and the tumor tissues were frozen 4 hours after the solvent was administered. The other groups were all given 100 mg / kg of the compound represented by formula (A), and the tumor tissues were frozen at 0.25h, 1h, 4h, 8h, 12h and 24h.
[0309] 1.4 Protein extraction and quantification
[0310] Take a certain amount of tumor tissue and add the corresponding volume of protein lysis buffer (RIPA lysis buffer (ThermoFisher, catalog number 89900): protease inhibitor (cOmplete, Mini, EDTA-free, EASY pack; Roche, catalog number 04693159001): phosphatase inhibitor (PhosStop, EASY pack; Roche, catalog number 04906837001) = 8:1:1), homogenize, and lyse on ice for 30 minutes. Centrifuge at low temperature and high speed, and take the supernatant for BCA protein quantification (according to the BCA protein quantification kit (Tiangen, catalog number: #PA115-01)). Finally, adjust the protein concentration to a uniform concentration with the lysis buffer, add loading buffer, and boil at 100°C for 10 minutes.
[0311] 1.5 Western-blot
[0312] Use 4-20% 10-well precast gel; load 100 μg; electrophoresis at 140V for 1-1.5h; wet transfer at 300mA for 1.5h-2h; block with 5% BSA for 2-3h; incubate with primary antibody at 4°C overnight (Trk 1:5000, p-Trk, PLCγ1, p-PLCγ1, AKT, p-AKT, actin 1:1000); wash with 0.1% TBST for 4×5min; incubate with secondary antibody at room temperature for 2h (1:5000), ECL luminescence, and expose.
[0313]
[0314]
[0315] 2. Test results: Fig. 9 shown.
[0316] The test results show that: as time goes by, Fig. 9 The expression of TRK, p-TRK, p-PLCγ1 and p-AKT in the culture medium were significantly reduced, which proved that the compound represented by formula (A) can significantly reduce the protein levels of TRK and p-TRK, and then effectively inhibit the phosphorylation of p-PLCγ1 / PLCγ1 and p-AKT / AKT to regulate cell growth and proliferation.
[0317] Experimental Example 5: In vivo efficacy study of compounds on NTRK mutation-resistant tumor models
[0318] Test methods
[0319] 1.1 Model preparation
[0320] Cells in the logarithmic growth phase were collected and resuspended in serum-free medium to a cell concentration of 6 × 10 7 -10×10 7 / mL, and add an equal volume of Matrigel to the cell suspension to make the final concentration of cells 3×10 7 -5×10 7 NuNu mice (Beijing Weitong Lihua, 4-6 weeks old, female) were subcutaneously inoculated with 0.1 mL of tumor cell suspension in the axilla of the forelimb, with an inoculation volume of 3×10 6 -5×10 6 To prepare the animal model.
[0321] 1.2 Trial Grouping
[0322] The maximum and minimum tumor diameters of the nude mouse transplanted tumor were measured with a vernier caliper to calculate the tumor volume: The calculation formula for tumor volume (TV) is: V = 1 / 2 × a × b 2 , where a and b represent the maximum and minimum diameters of the tumor, respectively. Nude mice with appropriate tumor volumes were selected and randomly divided into 7 groups (100-200 mm 3 ), 6 in each group.
[0323] 1.3 Observation indicators
[0324] On the day of grouping, animals were gavaged and administered according to their body weight. The administration volume was 10 mL / kg. LOXO-195 was prepared into the required administration solution using 0.5% CMC-Na, and the compound represented by formula (A) was prepared into the required administration solution using "3% DMSO + 96% HP-β-CD (0.5 g / mL) + 1% HCL". Tumor diameter was measured twice a week and tumor volume was calculated. Specific indicators are as follows:
[0325] Animal body weight: Animals were weighed every morning before administration. A weight loss greater than 20% was defined as a toxic reaction to the drug (observed until the day after the last administration);
[0326] Tumor volume (TV) = V = 1 / 2 × a × b 2 , where a and b represent the maximum and minimum diameters of the tumor mass, respectively (observed until the day after the last administration);
[0327] Relative tumor proliferation rate T / C (%): T / C (%) = TRTV / CRTV × 100% (TRTV: RTV of the treatment group, CRTV: RTV of the control group);
[0328] Tumor growth inhibition rate (TGI) = [1-(Ti-T0) / (Vi-V0)] × 100%. (Ti represents the average tumor volume of a certain dosing group on a certain day; T0 is the average tumor volume of this dosing group at the beginning of dosing; Vi is the average tumor volume of the vehicle control group on a certain day (the same day as Ti); V0 is the average tumor volume of the vehicle control group at the beginning of dosing);
[0329] Tumor inhibition rate: At the end of the experiment, the animals were killed by cervical dislocation, the tumor masses were removed and weighed, and photos were taken to calculate the tumor inhibition rate, which was (tumor inhibition rate = (average tumor weight of the control group - average tumor weight of the drug-treated group) / average tumor weight of the control group × 100%).
[0330] Test results
[0331] 2.1Ba / F3 LMNA-NTRK1-G667C model
[0332] 2.1.1 Effects of drugs on the body weight of tumor-bearing mice
[0333] The body weight of each compound and each dose group has an upward trend, and the upward trend is more obvious than that of the control group. The body weight of each compound and each dose group increased significantly, which may be related to the compound, or it may be due to the inhibition of tumor growth, which makes the mice in better condition and has obvious weight gain. The results are shown in Table 12.
[0334] 2.1.2 Effects of drugs on tumor weight and tumor inhibition rate in tumor-bearing mice
[0335] The data results show that: at the same dosage (100 mg / kg), the compound represented by formula (A) has a more significant inhibitory effect on tumor growth compared with LOXO-195; further, compared with the LOXO-195 group with a higher dosage (200 mg / kg), the compound represented by formula (A) (100 mg / kg) also exhibits a better tumor inhibition effect. The results are shown in Table 12.
[0336] Table 12 In vivo results of Ba / F3 LMNA-NTRK1-G667C model
[0337]
[0338]
[0339] 2.2Ba / F3 LMNA-NTRK1-G595R model
[0340] 2.2.1 Effects of drugs on body weight of tumor-bearing mice
[0341] The body weight of each compound and each dose group has an upward trend, and the upward trend is more obvious than that of the control group. The body weight of each compound and each dose group increased significantly, which may be related to the compound, or it may be due to the inhibition of tumor growth, which makes the mice in better condition and has obvious weight gain. The results are shown in Table 13.
[0342] 2.2.2 Effects of drugs on tumor weight and tumor inhibition rate in tumor-bearing mice
[0343] The data results show that compared with LOXO-195 (100 mg / kg), the compound represented by formula (A) can achieve significant inhibition of tumor tissue weight at a lower dosage (50 mg / kg), with a tumor weight inhibition rate of >90%. The results are shown in Table 13.
[0344] Table 13 In vivo results of Ba / F3 LMNA-NTRK1-G595R model
[0345]
[0346] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A salt of a compound represented by formula (A-1), in, HA is an acid selected from hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid or benzenesulfonic acid; n is an integer or a half integer from 1 / 2 to 4.
2. The salt of the compound represented by formula (A-1) according to claim 1, in, HA is hydrochloric acid, sulfuric acid or methanesulfonic acid; and / or n is an integer or half integer of 1 / 2 to 3.
3. The salt of the compound represented by formula (A-1) according to claim 1, in, HA is hydrochloric acid or sulfuric acid; and / or n is 0.5, 1, 1.5 or 2.
4. The salt of the compound represented by formula (A-1) according to claim 1, in, The salt is a salt of the compound represented by formula (A-1) in a crystalline form.
5. A salt of the compound represented by formula (A-1) according to any one of claims 1 to 4, in, The salt is the hydrochloride of the compound represented by formula (1), Wherein, n is 0.5, 1, 1.5 or 2.
6. The salt of the compound represented by formula (A-1) according to claim 5, in, n is 1 or 2.
7. The salt of the compound represented by formula (A-1) according to claim 5, in, The salt is a hydrochloride represented by formula (1-1), 8. The salt of the compound represented by formula (A-1) according to claim 7, in, The salt is a hydrochloride salt represented by formula (1-1) in a crystalline form.
9. The salt of the compound represented by formula (A-1) according to claim 8, wherein the salt is the crystalline form I of the hydrochloride represented by formula (1-1), and using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 6.3°±0.2°, 11.6°±0.2°, 17.1°±0.2°, 19.1°±0.2°.
10. The salt of the compound represented by formula (A-1) according to claim 9, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 6.3°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 17.1°±0.2°, 19.1°±0.2°, 19.3°±0.2°.
11. The salt of the compound represented by formula (A-1) according to claim 9, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 6.3°±0.2°, 7.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.7°±0.2°, 17.1°±0.2°, 19.1°±0.2°, 19.3°±0.2°.
12. The salt of the compound represented by formula (A-1) according to claim 9, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 6.3°±0.2°, 7.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.7°±0.2°, 15.1°±0.2°, 17.1°±0.2°, 19.1°±0.2°, 19.3°±0.2°, 25.8°±0.2°.
13. The salt of the compound represented by formula (A-1) according to claim 9, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 6.3°±0.2°, 7.5°±0.2°, 11.6°±0.2°, 11.8°±0.2°, 12.7°±0.2°, 15.1°±0.2°, 16.3°±0.2°, 17.1°±0.2°, 19.1°±0.2°, 19.3°±0.2°, 24.7°±0.2°, 25.8°±0.2°.
14. The salt of the compound represented by formula (A-1) according to claim 9, in, The crystalline form I has an X-ray powder diffraction pattern substantially as shown in FIG1 .
15. A salt of the compound represented by formula (A-1) according to any one of claims 9 to 14, in, The differential scanning calorimetry curve of the crystal form I has an endothermic peak at 174.7±5°C.
16. A salt of the compound represented by formula (A-1) according to any one of claims 9 to 14, in, The crystalline form I has a DSC spectrum substantially as shown in FIG2 .
17. A salt of the compound represented by formula (A-1) according to any one of claims 1 to 4, in, The salt is a sulfate represented by formula (2), Wherein, n is 0.5 or 1.
18. The salt of the compound represented by formula (A-1) according to claim 17, wherein The salt is a sulfate represented by formula (2-1), 19. The salt of the compound represented by formula (A-1) according to claim 18, in, The salt is a sulfate salt represented by formula (2-1) in a crystalline form.
20. The salt of the compound represented by formula (A-1) according to claim 19, in, The salt is a crystalline form I of the sulfate represented by formula (2-1). Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 7.8°±0.2°, 17.5°±0.2°, 18.9°±0.2°, 19.7°±0.2°.
21. The salt of the compound represented by formula (A-1) according to claim 20, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 7.8°±0.2°, 17.5°±0.2°, 18.9°±0.2°, 19.7°±0.2°, 24.6°±0.2°.
22. The salt of the compound represented by formula (A-1) according to claim 20, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 7.8°±0.2°, 12.5°±0.2°, 17.5°±0.2°, 18.9°±0.2°, 19.7°±0.2°, 23.6°±0.2°, 24.6°±0.2°.
23. The salt of the compound represented by formula (A-1) according to claim 20, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 7.8°±0.2°, 12.5°±0.2°, 17.5°±0.2°, 18.9°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 23.6°±0.2°, 24.6°±0.2°, and 25.3°±0.2°.
24. The salt of the compound represented by formula (A-1) according to claim 20, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 5.7°±0.2°, 7.8°±0.2°, 12.5°±0.2°, 17.5°±0.2°, 18.9°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 23.6°±0.2°, 24.6°±0.2°, 25.3°±0.2°, and 26.1°±0.2°.
25. The salt of the compound represented by formula (A-1) according to claim 20, in, The crystalline form I has an X-ray powder diffraction pattern substantially as shown in FIG3 .
26. The salt of the compound represented by formula (A-1) according to claim 19, in, The salt is a crystalline form II of the sulfate represented by formula (2-1). Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.5°±0.2°, 7.6°±0.2°, 16.5°±0.2°, 18.9°±0.2°.
27. The salt of the compound represented by formula (A-1) according to claim 26, in, The X-ray powder diffraction pattern of the crystalline form II has characteristic diffraction peaks at the following 2θ angles: 3.9°±0.2°, 5.5°±0.2°, 7.6°±0.2°, 16.5°±0.2°, 18.9°±0.2°.
28. The salt of the compound represented by formula (A-1) according to claim 26, in, The X-ray powder diffraction pattern of the crystalline form II has characteristic diffraction peaks at the following 2θ angles: 3.9°±0.2°, 5.5°±0.2°, 7.6°±0.2°, 10.9°±0.2°, 16.5°±0.2°, 18.9°±0.2°.
29. The salt of the compound represented by formula (A-1) according to claim 26, in, The X-ray powder diffraction pattern of the crystalline form II has characteristic diffraction peaks at the following 2θ angles: 3.9°±0.2°, 5.5°±0.2°, 7.6°±0.2°, 10.9°±0.2°, 16.0°±0.2°, 16.5°±0.2°, 18.9°±0.2°.
30. The salt of the compound represented by formula (A-1) according to claim 26, in, The X-ray powder diffraction pattern of the crystalline form II has characteristic diffraction peaks at the following 2θ angles: 3.9°±0.2°, 5.5°±0.2°, 7.6°±0.2°, 10.9°±0.2°, 12.6°±0.2°, 16.0°±0.2°, 16.5°±0.2°, 18.9°±0.2°.
31. The salt of the compound represented by formula (A-1) according to claim 26, in, The crystalline form II has an X-ray powder diffraction pattern substantially as shown in FIG5 .
32. A salt of the compound represented by formula (A-1) according to any one of claims 26 to 31, in, The differential scanning calorimetry curve of the crystal form II has an endothermic peak at 227.22±5°C.
33. A salt of the compound represented by formula (A-1) according to any one of claims 26 to 31, in, The crystalline form II has a DSC spectrum substantially as shown in FIG6 .
34. A salt of the compound represented by formula (A-1) according to any one of claims 1 to 4, in, The salt is a methanesulfonate salt represented by formula (3), Wherein, n is 0.5, 1, 1.5 or 2.
35. The salt of the compound represented by formula (A-1) according to claim 34, in, n is 1; The salt is a methanesulfonate salt represented by formula (3-1), 36. The salt of the compound represented by formula (A-1) according to claim 35, in, The salt is a mesylate salt represented by formula (3-1) in a crystalline form.
37. The salt of the compound represented by formula (A-1) according to claim 36, in, The salt is the crystalline form I of the mesylate salt represented by formula (3-1). Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.8°±0.2°, 8.1°±0.2°, 10.6°±0.2°, 11.9°±0.2°.
38. The salt of the compound represented by formula (A-1) according to claim 37, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 6.8°±0.2°, 8.1°±0.2°, 10.6°±0.2°, 11.9°±0.2°, and 15.5°±0.2°.
39. The salt of the compound represented by formula (A-1) according to claim 37, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 6.8°±0.2°, 8.1°±0.2°, 10.6°±0.2°, 11.9°±0.2°, 15.5°±0.2°, 18.9°±0.2°, 21.1°±0.2°.
40. The salt of the compound represented by formula (A-1) according to claim 37, in, The X-ray powder diffraction pattern of the crystalline form I has characteristic diffraction peaks at the following 2θ angles: 6.8°±0.2°, 8.1°±0.2°, 10.6°±0.2°, 11.9°±0.2°, 15.5°±0.2°, 18.0°±0.2°, 18.9°±0.2°, 21.1°±0.2°, 26.3°±0.2°.
41. A salt of the compound represented by formula (A-1) according to claim 37, in, The crystalline form I has an X-ray powder diffraction pattern substantially as shown in FIG. 7 .
42. A salt of the compound represented by formula (A-1) according to any one of claims 37 to 41, in, The differential scanning calorimetry curve of the crystal form I has an endothermic peak at 180.62±5°C.
43. A salt of the compound represented by formula (A-1) according to any one of claims 37 to 41, in, The crystalline form I has a DSC spectrum substantially as shown in FIG8 .
44. A pharmaceutical composition comprising a salt of the compound represented by formula (A-1) according to any one of claims 1 to 43.
45. The pharmaceutical composition according to claim 44, in, The pharmaceutical composition comprises one or more pharmaceutically acceptable carriers.
46. Use of a salt of a compound represented by formula (A-1) according to any one of claims 1 to 43 or a pharmaceutical composition according to any one of claims 44 to 45 in the preparation of a drug; The drug is a TRK, ROS1 or ALK inhibitor.
47. The use according to claim 46, in, The medicine is a medicine for treating pain diseases, cell proliferation diseases, inflammatory diseases, neurodegenerative diseases or infectious diseases.
48. The use according to claim 47, in, The cell proliferative disease is a tumor.
49. The use according to claim 48, in, The tumor is a solid tumor or a blood tumor.
50. The use according to claim 49, in, The tumor is a hematological malignancy, lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, glioma, colorectal cancer, melanoma, cancer of the head and neck, gallbladder cancer, thyroid cancer, malignant glioma, gastric cancer, neuroblastoma or salivary gland cancer.
51. The use according to claim 50, in, The lung cancer is non-small cell lung cancer.
52. Use according to any one of claims 47 to 51, in, The disease involves NTRK, ALK, ROS1 or a combination of gene fusion, amplification, rearrangement, mutation or high expression.
53. Use according to any one of claims 47 to 51, in, The disease is mediated by one, two or three of TRKA, TRKB or TRKC.
54. Use according to any one of claims 47 to 51, in, The disease involves dysregulation of NTRK genes, TRK proteins, or their expression, activity or levels.
55. Use according to any one of claims 47 to 51, in, The disease involves NTRK gene fusion, amplification, rearrangement, mutation or high expression.
56. The use according to claim 52, in, The NTRK mutation is NTRK1-G595R, NTRK1-G667C, NTRK3-G623R or NTRK3-G696A.
57. The use according to claim 54, in, The NTRK mutation is NTRK1-G595R, NTRK1-G667C, NTRK3-G623R or NTRK3-G696A.
58. The use according to claim 55, in, The NTRK mutation is NTRK1-G595R, NTRK1-G667C, NTRK3-G623R or NTRK3-G696A.
59. Use according to any one of claims 47 to 51, in, The disease involves dysregulation of the ROS1 gene, ROS1 protein, or their expression, activity or level.
60. Use according to any one of claims 47 to 51, in, The disease involves ROS1 gene fusion, amplification, rearrangement, mutation or high expression.
61. A method for preparing a salt of a compound represented by formula (A-1) according to any one of claims 1 to 43, comprising reacting the compound represented by formula (A) with an acid in a reaction solvent, and isolating the salt of the compound represented by formula (A-1): in, HA is selected from hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid or benzenesulfonic acid; n is n in any one of claims 1 to 43.
62. The preparation method according to claim 61, in, The molar ratio of the compound represented by formula (A) to HA is 1-2:0.5-2; The reaction solvent is selected from one or a combination of two of alcohols, esters, nitriles, ketones, water or heterocycloalkane solvents.
Citation Information
Patent Citations
Compounds and compositions as TRK inhibitors
WO2012034095A1
Substituted pyrazolopyrimidines useful as kinases inhibitors
WO2019029629A1
Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors
CN102264736A
Preparation and application of imidazo aromatic ring compounds
CN111039946A
Substituted pyrazolopyrimidines useful as kinases inhibitors
CN111542522A
